Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity

Drug Metabolism and Disposition

Volumn 28, Issue 5, 2000, Pages 567-572

  Tang, Cuyue ^a   Shou, Magang ^a   Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; CELECOXIB; CYTOCHROME P450; DICLOFENAC; FLUNITRAZEPAM; FLURBIPROFEN; HEXOBARBITAL; OXYGENASE; PHENYTOIN; SOLVENT; TOLBUTAMIDE; WARFARIN;

ARTICLE; CATALYSIS; DRUG ACTIVITY; ENZYME SUBSTRATE; HYDROXYLATION; LIPOPHILICITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SOLUBILITY;

ACETONITRILES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MICROSOMES, LIVER; PHENOTYPE; PHENYTOIN; PYRAZOLES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFONAMIDES; TOLBUTAMIDE;

EID: 0034007499     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bort R, Mace K, Boobis A, Gomez Lechon MJ, Pfeifer A and Castell-J (1999) Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58:787-796.
2. Busby WF Jr, Ackermann JM and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249.
3. Carlile DJ, Hakooz N, Bayliss MK and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625-635.
4. Chaurel N, Gauthier A and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4.
5. Coller JK, Somogyi AA and Bochner F (1999) Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4. Xenobiotica 29:973-986.
6. Cotreau-Bibbo MM, von Moltke LL and Greenblatt-DJ (1996) Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. J Pharm Sci 85:1180-1185.
7. Crewe HK, Ellis SW, Lennard MS and Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178.
8. Draper AJ, Madan A and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
9. Gelboin HV, Park SS and Battula N (1988) DNA recombinant and monoclonal antibody directed methods for determining cytochrome P-450 specificity. Biochem Pharmacol 37:98-102.
10. Gerhards E and Gibian H (1967) The metabolism of dimethyl sulfoxide and its metabolic effects in man and animals. Ann NY Acad Sci 141:65-76.
11. Goldstein JA and de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
12. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
13. Haining RL, Jones JP, Koop DR, Trager WF and Rettie AE (1996) Determinants of substrate and inhibitor specificities of human CYP2C9. ISSX Proc 10:236.
14. Hickman D, Wang JP, Wang Y and Unadkat-JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
15. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochen Pharmacol 47:1469-1479.
16. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041-1050.
17. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
18. Leatherbarrow RJ (1992) GraFit Version 3.0, Erithacus Software Ltd., Staines, UK.
19. Leemann T, Transon C and Dayer P (1993) Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
20. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
21. Mei Q, Tang C, Assang C, Slaughter D, Rodrigues DA, Rushmore TH and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
22. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
23. Nielsen KK, Flinois JP, Beaune P and Brosen K (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277:1659-1664.
24. Palamanda J, Feng WW, Lin CC and Nomeir AA (2000). Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metab Dispos 28:38-43.
25. Rochat B, Amey M, Gillet M, Meyer UA and Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10.
26. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
27. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
28. Tang C, Shou M, Mei Q, Rushmore TH and Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453-459.
29. Teschke R, Hasumura Y and Lieber CS (1975) Hepatic microsomal alcohol-oxidizing system. Affinity for methanol, ethanol, propanol, and butanol. J Biol Chem 250:7397-7404.
30. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ and Korzekwa KR (1996) Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52:1305-1309.
31. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA and Birkett DJ (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-538.
32. Wong BK, Goldstein J, Spielberg SP and Rushmore TH (1996) Characterization of an in vitro model for assessing mechanism of deficient losartan metabolism. ISSX Proc 10:236.
33. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56:243-251.
34. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165-172.